New PET scan could spot hidden heart disease
NCT ID NCT07538518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special PET-CT scan using a drug called evuzamitide can detect signs of cardiac amyloidosis in people whose standard heart scans were unclear but who have high levels of a blood marker called TAD1. About 25 adults with heart failure or a genetic risk for this condition will receive one scan and be followed for about a month. The goal is to improve diagnosis for this serious heart disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOGENIC TRANSTHYRETIN (ATTR) AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bill and Rita Clements Advanced Medical Imaging Center
Dallas, Texas, 75235-8823, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
One Boston Medical Center Place
Boston, Massachusetts, 02118, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver clues: a new way to stage heart amyloidosis?
- A carpal tunnel clue to a silent heart threat?
- Can a daily pill keep a rare heart disease in check for the long haul?
- Heart scans may unlock hidden risks in minority communities
- Pacemaker signals may unmask a rare heart condition
- Can an AI spot hidden heart disease that doctors miss?